Diabetes Metab J.  2019 Feb;43(1):97-104. 10.4093/dmj.2018.0030.

Soluble Dipeptidyl Peptidase-4 Levels Are Associated with Decreased Renal Function in Patients with Type 2 Diabetes Mellitus

• Cho EH
• Kim SW

• KMID: 2460976
• DOI: http://doi.org/10.4093/dmj.2018.0030

Abstract

BACKGROUND
Dipeptidyl peptidase-4 (DPP-4) is strongly expressed in the kidney, and soluble levels of this protein are used as a marker in various chronic inflammatory diseases, including diabetes, coronary artery disease, and cancer. This study examined the association between the serum soluble DPP-4 levels and renal function or cardiovascular risk in patients with type 2 diabetes mellitus.
METHODS
In this retrospective analysis, soluble DPP-4 levels were measured in preserved sera from 140 patients with type 2 diabetes mellitus who had participated in our previous coronary artery calcium (CAC) score study.
RESULTS
The mean±standard deviation soluble DPP-4 levels in our study sample were 645±152 ng/mL. Univariate analyses revealed significant correlations of soluble DPP-4 levels with the total cholesterol (r=0.214, P=0.019) and serum creatinine levels (r=−0.315, P<0.001) and the estimated glomerular filtration rate (eGFR; estimated using the modification of diet in renal disease equation) (r=0.303, P=0.001). The associations of soluble DPP-4 levels with serum creatinine and GFR remained significant after adjusting for age, body mass index, and duration of diabetes. However, no associations were observed between soluble DPP-4 levels and the body mass index, waist circumference, or CAC score.
CONCLUSION
These data suggest the potential use of serum soluble DPP-4 levels as a future biomarker of deteriorated renal function in patients with type 2 diabetes mellitus.

Keyword

Diabetes mellitus, type 2; Dipeptidyl peptidase 4; Glomerular filtration rate; Kidney

MeSH Terms

Body Mass Index
Calcium
Cholesterol
Coronary Artery Disease
Coronary Vessels
Creatinine
Diabetes Mellitus, Type 2*
Diet
Dipeptidyl Peptidase 4
Glomerular Filtration Rate
Humans
Kidney
Retrospective Studies
Waist Circumference
Calcium
Cholesterol
Creatinine
Dipeptidyl Peptidase 4

Figure

• 

  Fig. 1 Correlation between serum soluble dipeptidyl peptidase-4 (sDPP-4) levels and (A) serum creatinine or (B) estimated glomerular filtration rate (GFR) calculated by modification of diet in renal disease (MDRD) equation.

Reference

1. Lambeir AM, Durinx C, Scharpe S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003; 40:209–294. PMID: 12892317.

2. Hopsu-Havu VK, Glenner GG. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie. 1966; 7:197–201. PMID: 5959122.

3. Deacon CF. What do we know about the secretion and degradation of incretin hormones? Regul Pept. 2005; 128:117–124. PMID: 15780431.

4. Mentlein R. Dipeptidyl-peptidase IV (CD26): role in the inactivation of regulatory peptides. Regul Pept. 1999; 85:9–24. PMID: 10588446.

5. Jungraithmayr W, De Meester I, Matheeussen V, Baerts L, Arni S, Weder W. CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation. Eur J Cardiothorac Surg. 2012; 41:1166–1173. PMID: 22219460.

6. Lambeir AM, Proost P, Durinx C, Bal G, Senten K, Augustyns K, Scharpe S, Van Damme J, De Meester I. Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J Biol Chem. 2001; 276:29839–29845. PMID: 11390394.

7. Reinehr T, Roth CL, Enriori PJ, Masur K. Changes of dipeptidyl peptidase IV (DPP-IV) in obese children with weight loss: relationships to peptide YY, pancreatic peptide, and insulin sensitivity. J Pediatr Endocrinol Metab. 2010; 23:101–108. PMID: 20432813.

8. Shi S, Srivastava SP, Kanasaki M, He J, Kitada M, Nagai T, Nitta K, Takagi S, Kanasaki K, Koya D. Interactions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transition. Kidney Int. 2015; 88:479–489. PMID: 25830763.

9. Zhong J, Rao X, Rajagopalan S. An emerging role of dipeptidyl peptidase 4 (DPP-4) beyond glucose control: potential implications in cardiovascular disease. Atherosclerosis. 2013; 226:305–314. PMID: 23083681.

10. Rohrborn D, Eckel J, Sell H. Shedding of dipeptidyl peptidase 4 is mediated by metalloproteases and up-regulated by hypoxia in human adipocytes and smooth muscle cells. FEBS Lett. 2014; 588:3870–3877. PMID: 25217834.

11. Durinx C, Lambeir AM, Bosmans E, Falmagne JB, Berghmans R, Haemers A, Scharpe S, De Meester I. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/ dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem. 2000; 267:5608–5613. PMID: 10951221.

12. Cordero OJ, Salgado FJ, Nogueira M. On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol Immunother. 2009; 58:1723–1747. PMID: 19557413.

13. Lamers D, Famulla S, Wronkowitz N, Hartwig S, Lehr S, Ouwens DM, Eckardt K, Kaufman JM, Ryden M, Muller S, Hanisch FG, Ruige J, Arner P, Sell H, Eckel J. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes. 2011; 60:1917–1925. PMID: 21593202.

14. Duvnjak L, Blaslov K, Vucic Lovrencic M, Knezevic Cuca J. Persons with latent autoimmune diabetes in adults express higher dipeptidyl peptidase-4 activity compared to persons with type 2 and type 1 diabetes. Diabetes Res Clin Pract. 2016; 121:119–126. PMID: 27693949.

15. Yang G, Li Y, Cui L, Jiang H, Li X, Jin C, Jin D, Zhao G, Jin J, Sun R, Piao L, Xu W, Fang C, Lei Y, Yuan K, Xuan C, Ding D, Cheng X. Increased plasma dipeptidyl peptidase-4 activities in patients with coronary artery disease. PLoS One. 2016; 11:e0163027. PMID: 27654253.

16. Zheng T, Liu Y, Qin S, Liu H, Yang L, Zhang X, Li G, Li Q. Increased dipeptidyl peptidase-4 activity is associated with high prevalence of depression in middle-aged and older adults: a cross-sectional study. J Clin Psychiatry. 2016; 77:e1248–e1255. PMID: 27529287.

17. Kim SW, Cho EH. High levels of serum DPP-4 activity are associated with low bone mineral density in obese postmenopausal women. Endocrinol Metab (Seoul). 2016; 31:93–99. PMID: 26676330.

18. Landis BN, Grouzmann E, Monod M, Busso N, Petak F, Spiliopoulos A, Robert JH, Szalay-Quinodoz I, Morel DR, Lacroix JS. Implication of dipeptidylpeptidase IV activity in human bronchial inflammation and in bronchoconstriction evaluated in anesthetized rabbits. Respiration. 2008; 75:89–97. PMID: 17637510.

19. Hasegawa G, Nakano K, Sawada M, Uno K, Shibayama Y, Ienaga K, Kondo M. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int. 1991; 40:1007–1012. PMID: 1762301.

20. Lee SH, Ihm CG, Sohn SD, Lee TW, Kim MJ, Koh G, Oh SJ, Woo JT, Kim SW, Kim JW, Kim YS, Lee BC, Kim SD, Cho BS, Lee HJ, Chung JH. Polymorphisms in interleukin-1 beta and interleukin-1 receptor antagonist genes are associated with kidney failure in Korean patients with type 2 diabetes mellitus. Am J Nephrol. 2004; 24:410–414. PMID: 15286433.

21. Elmarakby AA, Sullivan JC. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther. 2012; 30:49–59. PMID: 20718759.

22. Sayyed SG, Hagele H, Kulkarni OP, Endlich K, Segerer S, Eulberg D, Klussmann S, Anders HJ. Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes. Diabetologia. 2009; 52:2445–2454. PMID: 19707743.

23. Lin S, Teng J, Li J, Sun F, Yuan D, Chang J. Association of chemerin and vascular endothelial growth factor (VEGF) with diabetic nephropathy. Med Sci Monit. 2016; 22:3209–3214. PMID: 27612613.

24. Girardi AC, Degray BC, Nagy T, Biemesderfer D, Aronson PS. Association of Na(+)-H(+) exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule. J Biol Chem. 2001; 276:46671–46677. PMID: 11590171.

25. Lee JW, Chou CL, Knepper MA. Deep sequencing in microdissected renal tubules identifies nephron segment-specific transcriptomes. J Am Soc Nephrol. 2015; 26:2669–2677. PMID: 25817355.

26. Nistala R, Savin V. Diabetes, hypertension, and chronic kidney disease progression: role of DPP4. Am J Physiol Renal Physiol. 2017; 312:F661–F670. PMID: 28122713.

27. Rohrborn D, Wronkowitz N, Eckel J. DPP4 in diabetes. Front Immunol. 2015; 6:386. PMID: 26284071.

28. Busso N, Wagtmann N, Herling C, Chobaz-Peclat V, Bischof-Delaloye A, So A, Grouzmann E. Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. Am J Pathol. 2005; 166:433–442. PMID: 15681827.

29. Kobayashi H, Hosono O, Mimori T, Kawasaki H, Dang NH, Tanaka H, Morimoto C. Reduction of serum soluble CD26/dipeptidyl peptidase IV enzyme activity and its correlation with disease activity in systemic lupus erythematosus. J Rheumatol. 2002; 29:1858–1866. PMID: 12233879.

30. Haluzik M, Frolik J, Rychlik I. Renal effects of DPP-4 inhibitors: a focus on microalbuminuria. Int J Endocrinol. 2013; 2013:895102. PMID: 24089613.

31. Barratt J, Topham P. Urine proteomics: the present and future of measuring urinary protein components in disease. CMAJ. 2007; 177:361–368. PMID: 17698825.

32. MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith TJ, McNeil KJ, Jerums G. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care. 2004; 27:195–200. PMID: 14693989.

33. Lee HW, Jo AR, Yi DW, Kang YH, Son SM. Prevalent rate of nonalbuminuric renal insufficiency and its association with cardiovascular disease event in Korean type 2 diabetes. Endocrinol Metab (Seoul). 2016; 31:577–585. PMID: 28029027.

34. Zheng T, Baskota A, Gao Y, Chen T, Tian H, Yang F. Increased plasma DPP4 activities predict new-onset hyperglycemia in Chinese over a four-year period: possible associations with inflammation. Metabolism. 2015; 64:498–505. PMID: 25592717.

35. Zheng T, Baskota A, Gao Y, Tian H, Yang F. Increased plasma dipeptidyl peptidase 4 activities predict new-onset microalbuminuria in association with its proinflammatory effects in Chinese without diabetes: a four-year prospective study. Nephrol Dial Transplant. 2015; 30:460–466. PMID: 25294850.

36. Boccardi V, Marano L, Rossetti RR, Rizzo MR, di Martino N, Paolisso G. Serum CD26 levels in patients with gastric cancer: a novel potential diagnostic marker. BMC Cancer. 2015; 15:703. PMID: 26471376.

37. Zheng T, Liu Y, Qin S, Liu H, Zhang X, Zhao H. Increased plasma dipeptidyl peptidase-4 activities are associated with high prevalence of diabetic nephropathy in Chinese patients with newly diagnosed type 2 diabetes: a cross-sectional study. Diab Vasc Dis Res. 2016; 13:127–136. PMID: 26821795.

38. Sun AL, Deng JT, Guan GJ, Chen SH, Liu YT, Cheng J, Li ZW, Zhuang XH, Sun FD, Deng HP. Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease. Diab Vasc Dis Res. 2012; 9:301–308. PMID: 22388283.

39. Carbone LD, Buzkova P, Fink HA, Robbins JA, Bethel M, Isales CM, Hill WD. Association of DPP-4 activity with BMD, body composition, and incident hip fracture: the Cardiovascular Health Study. Osteoporos Int. 2017; 28:1631–1640. PMID: 28150034.

40. Ahmed RH, Huri HZ, Al-Hamodi Z, Salem SD, Al-Absi B, Muniandy S. Association of DPP4 gene polymorphisms with type 2 diabetes mellitus in Malaysian subjects. PLoS One. 2016; 11:e0154369. PMID: 27111895.